Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
about
Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgGImmunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccineImmunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagersUpdated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityImpact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.Meningococcal conjugate vaccines: optimizing global impact.Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introductionProspects for eradication of meningococcal diseaseSeroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal.Prevention of meningococcal serogroup C disease by NeisVac-C.Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy.Advances with vaccination against Neisseria meningitidis.Glycoconjugate vaccines.Glycoconjugate vaccines: an update.A review of guidance on immunization in persons with defective or deficient splenic function.Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.Seroprotection against serogroup C meningococcal disease.Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa.
P2860
Q28741100-852FA0A2-E575-404C-BA30-AB81C9C8C7CEQ28749695-A82F7236-700F-404C-B7B0-CC5CDB468E80Q33397450-A92B2AED-80B6-4016-A750-BD49B4E20EE9Q33806774-B2323C91-BCDD-41E8-9CF5-166A1110E9C7Q33825722-644F6B8B-F536-4391-BDE8-EA16E26ADF43Q34033849-FB119681-0A74-4645-B16B-C2F6AB097C9FQ34153704-07C960A1-2A5D-41BC-B851-72B6DBB3AFA1Q34721179-3BBE1297-8D83-4033-A6F0-3A60A86A8AF5Q35547767-E7951CEE-6625-4D27-B161-2B8F19BB7360Q35598188-89D24B23-D90A-43EF-9DE7-BA6E918C6B83Q35739057-A1FDD7A7-77FD-49E8-B4A5-A5C9A11C25DCQ35803424-D1BF1242-B891-426B-8F9D-CC7AA1AFC04FQ35805284-690C6088-74C3-4EDE-AF68-257E8587EB46Q36083360-083F0FD0-CCB2-4FE2-B59F-8311E48EBB9EQ36154716-3964D1A9-68D4-4BC0-BAF8-BD4C9CB71944Q36440358-381E776A-8E81-4398-B2D6-3FD7126A01ACQ36974336-93C2CCF1-E1BA-4DC0-8349-CFA50EA3DC02Q37374692-58CA2CD4-C458-4669-8F7A-F20BD2363A41Q37403478-447402EC-F161-4AEB-85A7-CC390A803408Q37461347-4DEA8763-2B3B-4850-9476-B62C2A73D780Q37878485-D946A521-4EF6-4385-A6AA-6755BF77C5F5Q38040527-157F7700-336D-4C83-8CE1-4E60EB6A167AQ38044755-02C03600-C3D1-4AAE-B50F-B60F15680C01Q38286346-DC65FF56-D932-4B70-9F52-3E62A7E3C9DDQ38575340-C9DCB693-701F-4956-8B58-1055ED18313DQ38631381-73FD9571-30AA-498F-A70A-C53C9466A251Q38791439-01E17DD7-E266-4C80-AAD9-5FF1DD94B937Q39809312-3BFCA379-B417-4691-9198-ADE2FF7B0F9AQ41488993-313C8157-C6A3-416C-8BA7-6B01D2C47D3DQ42204205-4A398077-507D-42C3-A3EA-954D09A658E9Q42255158-2F4E3844-64CA-41FE-8A27-D396C9A5B3BDQ42270579-0DE93AA5-FA3A-48B3-B54C-F71320719EFAQ43077587-D2DD6C87-39AC-4AC4-AEC1-E1FB5C06A11BQ43876810-5B99671A-6FC6-4B86-BEEC-E64A9C0E1E1A
P2860
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Seroprotection against serogro ...... d Kingdom: observational study
@ast
Seroprotection against serogro ...... d Kingdom: observational study
@en
type
label
Seroprotection against serogro ...... d Kingdom: observational study
@ast
Seroprotection against serogro ...... d Kingdom: observational study
@en
prefLabel
Seroprotection against serogro ...... d Kingdom: observational study
@ast
Seroprotection against serogro ...... d Kingdom: observational study
@en
P2093
P2860
P1433
P1476
Seroprotection against serogro ...... d Kingdom: observational study
@en
P2093
A Borkowski
A J Pollard
P2860
P304
P356
10.1136/BMJ.39563.545255.AE
P407
P577
2008-06-05T00:00:00Z